PK MED

PK MED is a privately held, venture-backed French biotech developing a proprietary platform of tailor-designed, injectable, biodegradable micro-implants for localized drug delivery and cell homing. Its lead program, PKM-01 for gout flare, has received FDA clearance to initiate clinical development directly with a Phase 2 study via a 505(b)(2) pathway. The company's strategy leverages known drugs in novel delivery systems to create faster-acting, safer therapies with potentially abbreviated development timelines in areas with significant patient need and limited treatment options.

Proprietary platform for designing injectable, biodegradable micro-implants for localized, sustained drug delivery and for enhancing cell homing in bone marrow transplantation.

In gout, PKM-01 competes with oral NSAIDs, colchicine, steroids, and IL-1 inhibitors, differentiating through localized delivery. In OA, it would enter a crowded symptomatic treatment market but aims for the vacant DMOAD segment. The cell-homing approach for HSCT is more novel, facing competition from other conditioning regimens and gene therapies.